Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare eight-weeks glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0±9.6 years and 42.8±9.9 in Group A and B, respectively (p=0.74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (p=0.21). Five drop-outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated to SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short-term therapies. Short schedules with pangenotypic regimens could be a good approach to hard-to-reach populations, such as incarcerated patients.

Feasibility and efficacy of eight weeks Glecaprevir/Pibrentasvir to treat incarcerated viremic HCV patients: a case-control study / Fiore, Vito; Ranieri, Roberto; Dell'Isola, Serena; Pontali, Emanuele; Barbarini, Giorgio; Prestileo, Tullio; Marri, Daniele; Starnini, Giulio; Sotgiu, Giovanni; Madeddu, Giordano; Babudieri, Sergio. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - (2020). [10.1111/liv.14745]

Feasibility and efficacy of eight weeks Glecaprevir/Pibrentasvir to treat incarcerated viremic HCV patients: a case-control study

Fiore, Vito;Sotgiu, Giovanni;Madeddu, Giordano;Babudieri, Sergio
2020-01-01

Abstract

Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare eight-weeks glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0±9.6 years and 42.8±9.9 in Group A and B, respectively (p=0.74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (p=0.21). Five drop-outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated to SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short-term therapies. Short schedules with pangenotypic regimens could be a good approach to hard-to-reach populations, such as incarcerated patients.
Feasibility and efficacy of eight weeks Glecaprevir/Pibrentasvir to treat incarcerated viremic HCV patients: a case-control study / Fiore, Vito; Ranieri, Roberto; Dell'Isola, Serena; Pontali, Emanuele; Barbarini, Giorgio; Prestileo, Tullio; Marri, Daniele; Starnini, Giulio; Sotgiu, Giovanni; Madeddu, Giordano; Babudieri, Sergio. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - (2020). [10.1111/liv.14745]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/239857
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact